Multi-dose drug delivery device and method
First Claim
1. A drug delivery device comprising:
- at least two housing units connected together end-to-end in a fixed, linear orientation, each housing unit having an exterior surface and an interior surface, the exterior surfaces of the connected housing units defining a sidewall of the device;
at least two discrete dose units, each comprising a drug formulation comprising at least one drug, wherein each of the housing units has one of the discrete dose units disposed therewithin;
at least one degradable timing member connected to the at least two housing units and separating the discrete dose units from one another;
a first end piece defining a first end of the device; and
second end piece defining a second end of the device distal to the first end of the device, the discrete dose units being located between the first and second end pieces within each of the housing units,wherein the device, when deployed in vivo, is adapted to release a first of the at least two discrete dose units following rupture of the first or second end piece, and subsequently to release a second of the at least two discrete dose units following rupture of the at least one degradable timing member separating the first of the at least two discrete dose units from the second of the at least two discrete dose units.
3 Assignments
0 Petitions
Accused Products
Abstract
Drug delivery devices and methods are provided. The device included two or more housing units connected together end-to-end in a fixed, linear orientation, the exterior surfaces of the connected housing units defining a sidewall of the device; discrete drug dose units disposed within the housing units; degradable timing members connected to the housing units and separating the discrete dose units from one another; first and second end pieces defining opposed ends of the device such that the discrete dose units are located between the first and second end pieces within each of the housing units, wherein the device is configured to release in vivo a first of the discrete dose units following rupture of the first or second end piece, and subsequently to release in vivo a second of the discrete dose units following rupture of the degradable timing member separating the first discrete dose unit from the second discrete dose unit.
1125 Citations
17 Claims
-
1. A drug delivery device comprising:
-
at least two housing units connected together end-to-end in a fixed, linear orientation, each housing unit having an exterior surface and an interior surface, the exterior surfaces of the connected housing units defining a sidewall of the device; at least two discrete dose units, each comprising a drug formulation comprising at least one drug, wherein each of the housing units has one of the discrete dose units disposed therewithin; at least one degradable timing member connected to the at least two housing units and separating the discrete dose units from one another; a first end piece defining a first end of the device; and second end piece defining a second end of the device distal to the first end of the device, the discrete dose units being located between the first and second end pieces within each of the housing units, wherein the device, when deployed in vivo, is adapted to release a first of the at least two discrete dose units following rupture of the first or second end piece, and subsequently to release a second of the at least two discrete dose units following rupture of the at least one degradable timing member separating the first of the at least two discrete dose units from the second of the at least two discrete dose units. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
-
12. An implantable drug delivery device comprising:
-
at least two solid units of a drug formulation which comprises at least one drug, the solid units each having a proximal end, a distal end, and one or more longitudinal exterior surfaces therebetween; at least one seal member sandwiched between the proximal end of a first of the at least two solid units and the distal end of a second of the at least two solid units; and a coating layer covering at least the longitudinal exterior surfaces of the solid units, the coating layer being substantially non-permeable, wherein release of the drug from the first or second solid unit is controlled at least in part by the in vivo disintegration of the seal member. - View Dependent Claims (13, 14, 15, 16, 17)
-
Specification